Clinical trials: Shock
Covid19
Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection
Indication : Treatment of Subject with COVID-19 infection Phase : Phase I Duration of Study : 12 day Sample size : at least 15 subjects Methodology : Classical 3+3 design Investigational Product : MPT0B640, 15, 30, 60, 80 and…
- Trial name
- NCT04526717
- Testing
- MPT0B640
- Sponsor
- J Ints Bio
Cardiogenic Shock
Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock
This study is a prospective, multicenter, single-arm clinical trial conducted in China to evaluate the efficacy and safety of a novel left ventricular assist device, SynFlow Duro system, manufactured by ForQaly Medical in the…
- Trial name
- COURAGE (NCT07560085)
- Testing
- SynFlow Duro
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- ForQaly Medical (Shanghai) Co., Ltd
Cytokine Release Syndrome
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
- Trial name
- NCT04720378
- Testing
- ST266
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
This Phase 2 study tests whether adding two immune therapies - nogapendekin alfa-inbakicept (NAI) and off-the-shelf iNKT cell infusions - to standard care can safely help critically ill adults with severe community-acquired…
- Conditions
- Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
- Trial name
- NCT07492888
- Testing
- Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797)
- Sponsor
- ImmunityBio, Inc.
Septic Shock
Effect of Early Administration of Albumin 20% Versus Crystalloid
Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically…
- Trial name
- NCT06370078
- Testing
- Albumin Human
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Egymedicalpedia
Implantable Cardioverter Defibrillator(ICD)
To Evaluate the Delivery Timing Safety and Efficacy of AntiTachycardia Pacing (BIO|ATP)
To compare Treatment Group (settings of Early Multiple ATP) and Control Group (settings of extended detection time for the conventional ATP) in Japanese patients, and confirm their safety and efficacy
- Trial name
- BIO|ATP (NCT05426785)
- Testing
- 1:1 ratio for Treatment Group and Control Group
- Where
- Japan
- Volunteers
- 398 people
- Sponsor
- Biotronik SE & Co. KG
Candidemia, Mycoses
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).
- Conditions
- Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
- Trial name
- ReSTORE (NCT03667690)
- Testing
- Rezafungin for Injection, Caspofungin, Fluconazole
- Where
- 132 sites in United States, Argentina and 16 more
- Volunteers
- 199 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Cardiovascular Disease
Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming
The purpose of this clinical trial is to determine whether periodic therapy programming reports illustrating physician usage of shock reduction programming can increase utilization of recommended programming guidelines for…
- Trial name
- NCT00856349
- Testing
- Therapy Programming Report (TPR)
- Where
- 104 sites in United States, Argentina and 10 more
- Volunteers
- 4,384 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hemorrhagic Shock
Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting
This study is designed to assess the survival benefit of administering PolyHeme to severely injured trauma patients in hemorrhagic shock beginning in the prehospital setting, where blood is not available, and continuing…
- Trial name
- NCT00076648
- Testing
- Poly SFH-P Injection
- Where
- 32 sites in United States
- Sponsor
- Northfield Laboratories
Coronavirus Infection, Cytokine Storm
Yoga Pranayama Adjuvant to Treat Burden COVID-19
COronaVIrus Disease or Severe Acute Respiratory Syndrome -CoV-2 or COVID-19, mortality occurs mainly from immunological behavior or by suicide after healing .
- Conditions
- Coronavirus Infection, Cytokine Storm, Mental Disorder
- Trial name
- YOCO (NCT04413747)
- Testing
- morning Yoga-based breathing support, pre_lunch Yoga-based breathing support, pre_dinner Yoga-based breathing support
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Health Ricerca e Sviluppo S.R.L.
COVID-19
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
To provide ruxolitinib through an expanded access program for the treatment of cytokine storm due to COVID-19 in the United States to patients who are eligible but not able to be hospitalized or who are hospitalized with a…
- Trial name
- NCT04355793
- Testing
- Ruxolitinib
- Sponsor
- Incyte Corporation
Sepsis, Septic Shock
Leukocyte MOrphology and CORticosteroids Response in SEPtic Patients (MOCORSEP)
Non-interventional, prospective, monocentric study on the exploration of leukocyte morphological parameters according to the infectious condition and response to corticosteroid therapy of septic patients.
- Conditions
- Sepsis, Septic Shock, Sepsis Syndrome, Infection
- Trial name
- MOCORSEP (NCT04292431)
- Where
- France
- Volunteers
- 175 people
- Sponsor
- Beckman Coulter, Inc.
Sleep Apnea, Obstructive
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
- Trial name
- ACCCESS (NCT05592002)
- Testing
- Genio System
- Where
- 16 sites in United States
- Volunteers
- 124 people
- Sponsor
- Nyxoah S.A.
Sepsis, Septic Shock
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic…
- Trial name
- SYMON II (NCT06654895)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- Bluejay Diagnostics, Inc.
Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
VENUS: Septic Gene Expression Using SeptiCyte
The investigators seek to evaluate a new test for determining presence of infection/sepsis as compared to non-infection/systemic inflammatory response syndrome among critically ill patients within the first 24 hours of their…
- Trial name
- VENUS (NCT02127502)
- Where
- 6 sites in United States
- Volunteers
- 379 people
- Sponsor
- Immunexpress
Breast Cancer
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.
- Trial name
- NCT00627627
- Testing
- IPI-504
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- MedImmune LLC
Right Ventricular Infarction
The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients
This study is designed to better understand the effects of nitric oxide, a gas for inhalation, on patients with right ventricular infarction.
- Trial name
- NCT00782652
- Testing
- inhaled nitric oxide, nitrogen gas
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 3 people
- Sponsor
- Mallinckrodt
Sepsis, Septic Shock
ARTICE® Real Data Collection & Observational Trial, Phase 4 Study
The objectives of this registry study are to: 1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects. 2. Further evaluate ARTICE® treatment efficacy. 3.
- Conditions
- Sepsis, Septic Shock, Immunoparalysis in Septic Shock
- Trial name
- ARTistry (NCT07388628)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Artcline GmbH
Nephrolithiasis
Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy
The purpose of this study is to evaluate the efficacy of MP-5971 in facilitating stone passage after Shock Wave Lithotripsy treatment.
- Trial name
- NCT00860093
- Testing
- MPC-5971
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Mission Pharmacal